Three months of sleep disruption occurring three nights weekly defines chronic insomnia, requiring proven behavioral therapies over temporary medication options.
You wake up at two in the morning with your mind running while your body feels exhausted. You check the digital clock on the dresser and calculate how many hours remain before your alarm rings. You spent the day handling heavy workloads, physical training, and family responsibilities, yet sleep slips away the moment you try to force it. This pattern repeats several nights every week, leaving you searching for a reliable path back to consistent rest.
Cognitive behavioral therapy for insomnia provides the most durable, evidence-backed resolution for chronic sleep disruption, while medications offer short-term symptom relief that carries clear clinical trade-offs.
Clinical guidelines from the American College of Physicians, the American Academy of Sleep Medicine, and the Department of Veterans Affairs establish that structured behavioral interventions should serve as the first-line treatment for chronic insomnia. Prescription medications, over-the-counter sleep aids, and complementary therapies can alter short-term sleep patterns, but they do not correct the underlying neurological, behavioral, and cognitive mechanisms that sustain chronic sleep difficulty. Choosing the correct intervention requires evaluating symptom duration, safety profiles, daytime impairment, and the biological systems maintaining the problem.
Insomnia is clinically defined as persistent difficulty falling asleep, staying asleep, or waking up too early despite having adequate opportunity for rest. Occasional poor sleep is a normal response to acute stress, physical injury, travel, or demanding schedules. Chronic insomnia disorder, however, involves sleep disturbances occurring at least three nights per week for three months or longer, accompanied by meaningful daytime distress or impairment.
Daytime consequences often include reduced concentration, mood changes, decreased physical performance, and increased risk of accidents. For active personnel, veterans, and individuals with demanding routines, poor sleep directly interferes with physical readiness and mental clarity. Understanding your overall profile through our recovery and sleep resources can help you identify how physical strain and schedule disruption interact with nighttime wakefulness.
A comprehensive clinical assessment is necessary before starting any treatment. Insomnia should be evaluated through a detailed medical, psychiatric, and sleep history rather than quick guesswork. Clinicians evaluate bedtime routines, sleep-onset latency, frequency of nighttime awakenings, final wake times, and daytime napping habits. A two-week sleep diary serves as the foundation for this assessment. It records subjective sleep quality, time spent in bed, and patterns of night-to-night variability.
Assessment must also rule out or identify co-occurring conditions that disrupt sleep continuity. These conditions include obstructive sleep apnea, restless legs syndrome, gastroesophageal reflux, chronic joint or spine pain, and endocrine imbalances. Sleep apnea requires specific airway management rather than insomnia therapy alone. Movement disorders require targeted medical evaluation.
Psychiatric factors such as post-traumatic stress, generalized anxiety, major depressive disorder, and substance use must also be reviewed. Insomnia frequently coexists with these conditions rather than acting solely as a secondary symptom. Routine in-lab polysomnography is not required for standard chronic insomnia. Objective sleep testing is indicated when clinicians suspect underlying sleep apnea, nocturnal seizures, or periodic limb movement disorder.
Multicomponent cognitive behavioral therapy for insomnia, commonly known as CBT-I, is the definitive gold standard for chronic sleep disruption. Major medical authorities, including the American Academy of Sleep Medicine and the American College of Physicians, strongly recommend CBT-I as the initial intervention for adults. The 2025 VA/DoD clinical practice guideline specifically recommends CBT-I over pharmacotherapy as the first-line treatment for chronic insomnia disorder.
CBT-I is a structured, multi-week intervention designed to address the psychological, behavioral, and physiological systems that maintain insomnia over time. Unlike general sleep advice, CBT-I operates on a clear clinical framework. It systematically targets sleep scheduling, conditioned arousal, inaccurate sleep beliefs, and daily sleep-wake regulation.
Research demonstrates that CBT-I produces meaningful, lasting reductions in sleep difficulty. Meta-analytic data indicate average treatment effect sizes between 1.0 and 1.2, resulting in an approximate 50 percent reduction in individual insomnia symptoms across completed protocols. Clinical trials show short-term average improvements of 19 minutes in sleep-onset latency, 26 minutes in wake after sleep onset, and a 10 percentage point increase in overall sleep efficiency.
The critical advantage of CBT-I is its long-term durability. Sedative medications often lose efficacy once discontinued, but the behavioral and cognitive skills learned in CBT-I continue working for years. Long-term outcome data show that improvements in the Insomnia Severity Index remain stable at one-year and ten-year follow-up points. In extended clinical tracking, roughly two-thirds of participants who completed treatment no longer met the clinical criteria for chronic insomnia disorder a full decade later.
A 2024 systematic review confirmed that CBT-I achieved an odds ratio for long-term remission of 1.82 compared to pharmacotherapy, supported by high certainty of evidence. Medication acts primarily as an external, temporary sleep-promoting agent. CBT-I restores the body's natural homeostatic sleep drive and resets learned associations between the bed and mental alertness.
The behavioral components of CBT-I produce the fastest and most substantial improvements in sleep consolidation. Component network meta-analyses reveal that sleep restriction therapy and stimulus control are the most active drivers of improved sleep continuity and total sleep time.
Sleep restriction therapy limits the time a person spends in bed to match their actual average sleep duration. Many people with insomnia spend eight, nine, or ten hours in bed trying to capture six hours of fragmented sleep. This mismatch dilutes the homeostatic sleep drive and creates long periods of frustrating nighttime wakefulness.
If a sleep diary shows that an individual averages six hours of sleep while spending nine hours in bed, their initial prescribed sleep window is set closer to six hours. The wake time is anchored at a fixed hour every morning, regardless of how poorly the person slept the previous night. The individual goes to bed later in the evening to match the restricted window.
This intentional restriction rapidly increases homeostatic sleep pressure, which is the biological accumulation of adenosine in the central nervous system. As sleep pressure builds, sleep latency shortens, nighttime awakenings decrease, and sleep becomes consolidated.
As sleep efficiency (the percentage of time in bed spent asleep) rises above 85 to 90 percent, the clinician gradually extends the sleep window by 15 to 30 minutes per week. A network meta-analysis demonstrated that sleep restriction produces an effect size of d = -0.45 for reducing insomnia severity.
Sleep restriction requires sensible clinical safeguards. It temporarily causes daytime sleepiness, reduced reaction time, and mild irritability during the first two weeks of adjustment. Sleep restriction should be modified or carefully supervised for individuals operating heavy machinery, driving long commercial routes, or managing conditions like bipolar disorder or unstable epilepsy.
Stimulus control therapy operates on classical conditioning principles. When an individual spends weeks or months lying awake in bed worrying, checking the clock, and tossing around, the brain forms a conditioned association. The bed ceases to be a cue for sleep and instead becomes a biological trigger for alertness, frustration, and physiological hyperarousal.
Stimulus control breaks this unhelpful conditioned loop through several clear behavioral rules:
Leaving the bed during the night can feel counterproductive when you are exhausted. The objective, however, is not to maximize horizontal resting time. The objective is to ensure that every minute spent in bed is paired with actual sleep rather than conscious distress.
For individuals with mobility limitations or crowded living arrangements, stimulus control can be adapted. Sitting comfortably in a chair in the bedroom with low light while reading a printed book serves the same conditioning purpose as leaving the room entirely.
While behavioral interventions target sleep schedules and environmental cues, cognitive and physiological techniques address the psychological distress and autonomic hyperarousal that frequently accompany chronic insomnia.
Chronic insomnia generates catastrophic thinking patterns about the consequences of poor sleep. Individuals often develop rigid, anxiety-inducing beliefs that increase sympathetic nervous system activity before bedtime. These patterns create a state of performance anxiety around falling asleep.
Common unhelpful beliefs include:
Cognitive restructuring identifies, challenges, and reframes these extreme predictions. Through structured cognitive exercises, individuals examine the actual objective evidence behind their assumptions. They learn that while poor sleep causes fatigue, the human body can maintain baseline cognitive and physical function even after sub-optimal nights.
Component analyses show that cognitive restructuring primarily improves subjective sleep quality, reduces daytime performance anxiety, and lowers overall distress scores. It changes how a person interprets sleep disruption, which reduces the emotional arousal that keeps the brain awake.
Physiological hyperarousal is characterized by elevated evening cortisol levels, increased heart rate variability deficits, heightened body temperature, and continuous mental rumination. Relaxation techniques aim to downregulate the autonomic nervous system and facilitate the transition into stage 1 sleep.
Evidence-based counter-arousal techniques include:
Relaxation training carries a conditional recommendation from the American Academy of Sleep Medicine. It provides a practical, low-risk tool for individuals whose primary insomnia barrier is physical tension or acute racing thoughts.
Relaxation should not be viewed as an automatic switch for sleep. When people practice relaxation techniques with the urgent demand that sleep must occur immediately, relaxation becomes another stressful performance task. Recent component network meta-analyses indicate that relaxation alone does not reliably correct severe sleep fragmentation or long nighttime wakefulness. It works best as an supportive tool alongside sleep restriction and stimulus control.
Medication plays a defined role in clinical practice, but it requires careful management and realistic expectations. Clinical guidelines emphasize that pharmacotherapy should generally serve as a short-term, temporary measure or as an adjunct when CBT-I is inaccessible or incomplete.
The American College of Physicians recommends shared decision-making regarding the benefits, harms, and costs of short-term sleep medications. It advises that pharmacotherapy duration should generally be limited to four or five weeks. Understanding specific drug classes helps patients and clinicians make informed, risk-conscious choices.
Zolpidem, eszopiclone, and zaleplon are nonbenzodiazepine gamma-aminobutyric acid (GABA) receptor agonists. They act selectively on the GABA-A receptor complex to produce rapid sedation and decrease sleep-onset latency.
Clinical trials show that Z-drugs provide short-term improvements in sleep latency and total sleep time. However, effect sizes are generally small to moderate. These medications carry distinct clinical risks that require careful monitoring.
The U.S. Food and Drug Administration mandates a boxed warning for zolpidem, eszopiclone, and zaleplon due to the risk of complex sleep behaviors. Complex sleep behaviors include sleepwalking, sleep-driving, preparing food, making phone calls, and engaging in other activities while not fully awake. The FDA identified dozens of documented cases involving serious physical injuries and fatalities resulting from these automatic behaviors.
Patients who experience complex sleep behaviors must discontinue these medications immediately. Z-drugs also carry risks of physical tolerance, next-day cognitive slowing, balance impairment, and rebound insomnia upon sudden discontinuation.
Prescription benzodiazepines, such as temazepam and triazolam, are older agents that enhance GABA activity across a broader spectrum of receptor subtypes. While effective at inducing sedation, they significantly alter sleep architecture by suppressing deep slow-wave sleep and rapid eye movement (REM) sleep.
Benzodiazepines carry substantial risks of physical dependence, tolerance, memory impairment, daytime grogginess, and dangerous interactions with alcohol or other central nervous system depressants. In older adults or individuals with physical mobility issues, benzodiazepines significantly increase the incidence of nighttime falls and hip fractures. They are generally not recommended for extended use in routine chronic insomnia.
Dual orexin receptor antagonists represent a newer class of insomnia medications, including suvorexant, lemborexant, and daridorexant. Rather than forcing general sedation via the GABA pathway, DORAs block the binding of orexin neuropeptides, which are responsible for promoting and maintaining wakefulness in the hypothalamus.
By dampening the wake drive, DORAs assist patients with both sleep-onset and sleep-maintenance insomnia. The American College of Physicians evidence reviews highlight that suvorexant improves sleep latency, wake after sleep onset, and total sleep time compared to placebo.
DORAs do not carry the same degree of physical dependence or severe rebound risks seen with classic GABAergic sedatives. Documented side effects include next-day somnolence, headache, abnormal dreams, and, in rare instances, temporary sleep paralysis.
Low-dose doxepin (typically 3 mg to 6 mg) is approved for sleep-maintenance insomnia. At low doses, it acts as a selective histamine H1 receptor antagonist without exerting broad antidepressant actions. Clinical trials demonstrate improvements in wake after sleep onset and total sleep time, particularly in older adults, with a low risk of dependency.
Ramelteon is a selective melatonin MT1 and MT2 receptor agonist approved for sleep-onset difficulty. It mimics endogenous melatonin signaling in the suprachiasmatic nucleus of the hypothalamus. Ramelteon has no affinity for GABA receptors, does not cause physical dependence, and does not carry abuse potential, though its overall effect on total sleep duration is modest.
A significant percentage of insomnia prescriptions involve off-label medications, including trazodone, mirtazapine, quetiapine, gabapentin, and sedating antihistamines like diphenhydramine.
These medications are frequently prescribed to avoid the controlled-substance classification of standard hypnotics. However, robust evidence supporting their long-term efficacy for primary chronic insomnia is limited.
Antihistamines and sedating antidepressants can cause anticholinergic side effects, daytime drowsiness, dry mouth, urinary retention, and rapid tolerance. Atypical antipsychotics like quetiapine carry metabolic risks, including weight gain and lipid alterations, making them inappropriate as primary treatments for uncomplicated insomnia.
A clinical comparison between behavioral therapy and medication must evaluate more than immediate sleep onset. It must assess long-term efficacy, durability, safety profiles, patient effort, and clinical outcomes across several distinct dimensions.
CBT-I restructures conditioned cognitive arousal, aligns sleep scheduling with homeostatic sleep pressure, and restores the biological connection between the bed and sleep. Medication introduces an exogenous chemical agent to induce sedation or suppress wake-promoting neurotransmitters without changing sleep-related habits or beliefs.
Pharmacotherapy generally provides faster initial symptom relief, often reducing sleep latency within the first few nights of administration. CBT-I requires active learning and behavioral consistency, with meaningful sleep consolidation typically emerging between the second and fourth weeks of treatment.
CBT-I demonstrates superior durability. Clinical benefits persist or improve months and years after formal treatment concludes because the patient retains the behavioral tools and cognitive adaptations.
Medication benefits often decline upon discontinuation, frequently leading to rebound insomnia that patients mistake for a permanent biological inability to sleep. Long-term comparative trials consistently show higher remission rates for CBT-I compared to sustained hypnotic use.
CBT-I carries no chemical side effects, zero risk of chemical dependence, and no possibility of harmful drug-drug interactions. Its primary burden is the temporary daytime fatigue and irritability experienced during the early phases of sleep restriction.
Medications carry variable risks of daytime sedation, motor uncoordination, complex sleep behaviors, cognitive blunting, tolerance, and physical dependence. Medication requires clinical oversight to manage dosing, evaluate liver metabolism, and avoid dangerous interactions with alcohol or other sedating agents.
CBT-I requires sustained effort, daily sleep diary tracking, and active lifestyle modifications. It can be limited by the availability of trained behavioral sleep medicine specialists, though validated digital and group formats help bridge this gap.
Medication requires minimal behavioral effort, relying primarily on adherence to a dosing schedule. However, it requires ongoing prescription refills and clinical safety reviews.
In specific clinical scenarios involving severe distress or acute functional impairment, clinicians may initiate short-term pharmacotherapy concurrently with CBT-I. The medication provides immediate, temporary relief while the patient learns the behavioral core of CBT-I.
Guidelines emphasize tapering and discontinuing the medication once behavioral consolidation takes hold. Clinical trials show that combination therapy does not provide superior long-term outcomes compared to CBT-I delivered alone.
Many individuals turn to over-the-counter supplements, exercise routines, and alternative therapies to manage poor sleep. Evaluating these modalities requires separating established science from early research and unverified marketing claims.
Sleep hygiene includes standard lifestyle advice: keeping the bedroom cool, dark, and quiet; avoiding large meals before bed; limiting caffeine after midday; and avoiding alcohol late in the evening.
These habits remove environmental barriers to rest and support overall wellness. However, clinical trials demonstrate that sleep hygiene education alone is ineffective as a stand-alone treatment for chronic insomnia disorder.
The reason sleep hygiene fails as a solo therapy is straightforward. An individual can have a dark, quiet bedroom, eliminate all caffeine, and still lie awake for hours due to conditioned hyperarousal and poor sleep scheduling. Sleep hygiene provides a necessary baseline, but it lacks the active conditioning mechanisms found in sleep restriction and stimulus control.
Structured physical exercise is one of the most reliable lifestyle adjuncts for improving sleep architecture. Regular training deepens slow-wave sleep, supports healthy core body temperature rhythms, and lowers daytime anxiety levels.
A meta-analysis of 22 randomized controlled trials evaluated the effects of exercise on sleep quality. The analysis found statistically significant improvements across several standard clinical metrics:
For those maintaining rigorous strength and conditioning programs, reviewing our physical training and performance materials will help align physical exertion with adequate nighttime recovery. High-intensity cardiovascular or heavy resistance workouts should ideally be completed at least three to four hours before bedtime. Strenuous exercise elevates core temperature, heart rate, and sympathetic activation, which can delay sleep onset if performed immediately before bed.
Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Therapy for Insomnia (MBTI) use focused attention, body scanning, and non-judgmental awareness to reduce evening cognitive rumination.
Evidence for mindfulness as a stand-alone insomnia treatment remains mixed. The 2021 American Academy of Sleep Medicine guideline did not make a formal recommendation for mindfulness due to insufficient certainty of evidence.
Updated systematic reviews indicate that while mindfulness programs reliably reduce subjective stress, anxiety, and perceived sleep distress, they do not consistently alter objective sleep parameters like sleep efficiency or total sleep time. Mindfulness is best utilized as a supportive stress-reduction tool rather than an equivalent replacement for CBT-I.
Exogenous melatonin is widely used as a sleep aid, but its clinical utility is frequently misunderstood. Melatonin is a chronobiotic hormone produced by the pineal gland that signals biological night to the brain. It is not an intrinsically powerful hypnotic agent.
Evidence summaries from the American Academy of Sleep Medicine show that over-the-counter melatonin produces only minor reductions in sleep-onset latency (roughly 4 to 8 minutes) with minimal to no effect on wake after sleep onset or total sleep duration.
Melatonin is most effective for circadian rhythm sleep-wake disorders, such as delayed sleep-wake phase disorder, jet lag, and shift work transitions. It is less effective for primary chronic insomnia driven by conditioned arousal. Over-the-counter formulations frequently suffer from inaccurate dosing, with laboratory analyses finding substantial variance between the labeled dose and actual active content.
Herbal preparations are marketed heavily for sleep improvement, with valerian root being the most common. Clinical trials evaluating valerian have produced highly inconsistent results due to small sample sizes, lack of standardized extract concentrations, and high risk of study bias.
The American Academy of Sleep Medicine explicitly recommends against the use of valerian for chronic insomnia disorder due to inadequate evidence of efficacy and unestablished long-term safety profiles. Other botanicals, such as chamomile, passionflower, and ashwagandha, have preliminary data showing mild anti-anxiety effects, but they lack rigorous, large-scale clinical trials proving durable resolution of chronic insomnia.
Natural supplements are biologically active substances that can interact with prescription medicines and liver enzyme pathways. They should never be assumed to be inherently harmless simply because they are sold over the counter.
Complementary modalities such as acupuncture, acupressure, tai chi, and yoga are popular alternative approaches. Systematic reviews show that while these practices can improve subjective sleep quality and lower perceived stress, evidence regarding objective sleep architecture is inconclusive.
Acupuncture trials often suffer from methodological limitations, including inadequate sham-control designs and variable treatment protocols. These approaches can serve as pleasant, low-risk adjuncts for general stress management, provided they do not delay appropriate medical evaluation for sleep apnea or clinical insomnia.
Selecting the correct insomnia treatment requires matching the intervention to the individual's specific clinical presentation, work schedule, and physical environment.
A 42-year-old individual goes to bed at 9:00 p.m. wakes up at 6:30 a.m. but records only five and a half hours of actual sleep. They spend long periods awake checking the clock, reading on a tablet, and taking afternoon naps to compensate.
The primary maintaining mechanisms are poor sleep efficiency, weak homeostatic sleep pressure, and conditioned wakefulness.
The clinical plan prioritizes:
A 35-year-old individual reports feeling exhausted on the living room sofa at 9:30 p.m. However, the moment they lie down in bed, their heart rate increases and their mind begins racing about tomorrow's operational tasks.
The central issue is conditioned bedroom arousal paired with performance anxiety regarding sleep onset.
The clinical plan prioritizes:
A 50-year-old individual falls asleep easily at 10:00 p.m. but wakes abruptly at 3:00 a.m. and cannot return to sleep. They spend the remaining hours tossing in bed, feeling frustrated and exhausted.
The maintaining mechanism involves premature dissipation of homeostatic sleep drive combined with anxiety surrounding early awakening.
The clinical plan prioritizes:
A 48-year-old veteran reports severe nighttime awakenings, morning dry mouth, gasping for air, loud snoring, and heavy daytime fatigue. They request a prescription sleep aid to maintain sleep.
Prescribing a sedative-hypnotic in this scenario is hazardous because central nervous system depressants can worsen upper airway collapse and oxygen desaturation.
The clinical plan prioritizes:
Understanding these diagnostic priorities aligns with our broader military health priorities, ensuring that root physical causes are fully addressed before behavioral or drug therapies are applied.
Accessing behavioral sleep treatment has evolved beyond traditional weekly office visits. Multiple delivery formats now exist, providing flexible options for people with demanding schedules or remote locations.
Individual therapy delivered by a licensed psychologist or behavioral sleep medicine specialist provides the most customized intervention. The clinician analyzes weekly sleep diaries, adjusts sleep windows, addresses complex trauma or medical comorbidities, and offers personalized feedback.
Group CBT-I offers a structured, cost-effective alternative. Group formats provide peer accountability, shared learning, and consistent behavioral tracking. Component analyses confirm that group CBT-I produces clinical outcomes comparable to individual therapy.
Digital CBT-I platforms use automated algorithms or clinician-guided web modules to deliver sleep restriction calculations, stimulus control education, and cognitive restructuring exercises.
A 2024 meta-analysis demonstrated that digital CBT-I platforms produce statistically significant reductions in insomnia severity compared to control conditions. While in-person therapy generally achieves slightly higher adherence rates and subjective satisfaction, validated digital programs offer an accessible, scalable alternative for individuals who lack access to local specialists.
Consumers should distinguish clinically validated digital CBT-I platforms from generic commercial sleep-tracking apps. Basic smartphone sleep apps provide passive data logging without the structured behavioral modification protocols necessary to resolve chronic insomnia. You can find more structured tools in our sleep, stress, and resilience library.
Brief Behavioral Therapy for Insomnia is a streamlined, four-session intervention focused almost entirely on the behavioral mechanics of sleep restriction and stimulus control. It de-emphasizes extended cognitive restructuring in favor of rapid behavioral implementation.
BBTI is designed for primary care settings, occupational clinics, and military operational environments where time and mental health resources are limited. Clinical trials show that BBTI produces substantial improvements in sleep continuity, making it an efficient bridge when full multicomponent CBT-I is unavailable.
Applying evidence-based insomnia strategies requires consistent, methodical execution over several consecutive weeks. Use this step-by-step checklist to structure your sleep recovery plan starting this week.
Most individuals begin noticing improvements in sleep consolidation within two to four weeks of consistent behavioral application. The initial week of sleep restriction can cause temporary daytime tiredness as homeostatic sleep drive accumulates. Significant, durable reductions in insomnia severity are typically established by weeks four to six of a standard protocol.
Over-the-counter sleep aids containing antihistamines, such as diphenhydramine or doxylamine, are not recommended for chronic use. The human body develops tolerance to their sedating effects within days. Continued use can cause daytime cognitive slowing, dry mouth, blurred vision, urinary retention, and significant rebound insomnia once stopped.
Sleeping in on weekends disrupts your circadian pacemaker and drains the homeostatic sleep pressure needed for the following night. Shifting your wake-up time by several hours creates social jet lag, making it biologically difficult to fall asleep on Sunday evening and triggering a cycle of weekly insomnia.
Do not lie in bed watching the clock or calculating lost sleep. If you remain awake after approximately twenty minutes, get out of bed calmly and move to a dim, comfortable area. Engage in a low-stimulation activity, such as reading a physical book, until biological drowsiness returns, then return to bed.
Yes. Clinical guidelines specifically recommend CBT-I for individuals with co-occurring physical and psychiatric conditions, including chronic musculoskeletal pain, depression, and post-traumatic stress disorder. While managing underlying medical and psychological conditions is essential, CBT-I successfully treats the independent behavioral and cognitive factors that perpetuate sleep disruption.
This guide is provided strictly for educational purposes and is not a substitute for personalized clinical evaluation, medical diagnosis, or individualized treatment. Chronic insomnia frequently interacts with complex physiological, psychological, and pharmacological factors that require professional oversight.
Always consult a qualified healthcare professional, such as a primary care physician, sleep medicine specialist, or licensed mental health provider, before initiating sleep restriction protocols, tapering prescription medications, or adding dietary supplements. Discontinuing sedative-hypnotic medications abruptly can lead to severe withdrawal symptoms and dangerous rebound insomnia. A medical provider will help you safely manage treatment changes, screen for underlying sleep-related breathing disorders, and build a recovery plan tailored to your health profile.
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet
